Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review

Bibliography

• Pulford K, Morris SW, Turturro F. Anaplastic lymphoma kinase proteins in growth control and cancer. J Cell Physiol 2004;199:330-58
   PubMed Web of Science ®Google Scholar
• Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211-25
   PubMed Web of Science ®Google Scholar
• Yao S, Cheng M, Zhang Q, et al. Anaplastic lymphoma kinase is required for neurogenesis in the developing central nervous system of zebrafish. PLoS One 2013;8(5):e63757
   PubMed Web of Science ®Google Scholar
• Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994;263:1281-4
   PubMed Web of Science ®Google Scholar
• Chiarle R, Voena C, Ambrogio C, et al. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008;8:11-23
   PubMed Web of Science ®Google Scholar
• Piva R, Chiarle R, Manazza AD, et al. Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas. Blood 2006;107:689-97
   PubMed Web of Science ®Google Scholar
• Wan W, Albom MS, Lu L, et al. Anaplastic lymphoma kinase activity is essential for the proliferation and survival of anaplastic large-cell lymphoma cells. Blood 2006;107:1617-23
   PubMed Web of Science ®Google Scholar
• Weinstein IB. Addiction to oncogenes-the achilles heal of cancer. Science 2002;297:63-4
   PubMed Web of Science ®Google Scholar
• Webb TR, Slavish J, George RE, et al. Anaplastic lymphoma kinase: role in cancer pathogenesis and small molecule inhibitor development for therapy. Expert Rev Anticancer Ther 2009;9:331-56
   PubMed Web of Science ®Google Scholar
• Merkel O, Hamacher F, Sifft E, et al. Novel therapeutic options in anaplastic large cell lymphoma: molecular targets and immunological tools. Mol Cancer Ther 2011;10:1127-36
   PubMed Web of Science ®Google Scholar
• Grande E, Bolós M-V, Arriola E. Targeting oncogenic ALK: a promising strategy for cancer treatment. Mol Cancer Ther 2011;10:569-79
   PubMed Web of Science ®Google Scholar
• Giroux S. Overcoming acquired resistance to kinase inhibition: the cases of EGFR, ALK and BRAF. Bioorg Med Chem Lett 2013;23:394-01
   Google Scholar
• Kwak EL, Clark JW, Shaw AT. Targeted inhibition in tumors with ALK dependency. Lung Cancer 2013;4:1-8
   Google Scholar
• Shaw AT, Engelman JA. ALK in Lung cancer: past, present, and future. J Clin Oncol 2013;31:1105-11
   PubMed Web of Science ®Google Scholar
• Camidge DR, Doebele RC. Treating ALK-positive lung cancer-early successes and future challenges. Nat Rev Clin Oncol 2012;9:268-77
   PubMed Web of Science ®Google Scholar
• Milkiewicz KL, Ott GR. Inhibitors of anaplastic lymphoma kinase: a patent review. Expert Opin Ther Patents 2010;20:1653-81
   Web of Science ®Google Scholar
• Bang Y-J. Treatment of ALK-positive non–small cell lung cancer. Arch Pathol Lab Med 2012;136:1201-4
   PubMed Web of Science ®Google Scholar
• Cui JJ, Tran-Dube M, Shen H, et al. Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal−epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 2011;54:6342-63
   PubMed Web of Science ®Google Scholar
• Zou HY, Li Q, Lee JH, et al. An orally available small-molecule inhibitor of c-MET, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007;67:4408-17
   PubMed Web of Science ®Google Scholar
• Christensen JG, Zou HY, Arango ME, et al. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-MET, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007;6:3314-22
   PubMed Web of Science ®Google Scholar
• de la Bellacasa RP, Karachaliou N, Estrada-Tejedor R, et al. ALK and ROS1 as a joint target for the treatment of lung cancer: a review. Transl Lung Cancer Res 2013;2:72-86
   Google Scholar
• Shaw AT, Kim D-W, Nakagawa K. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013;368:2385-94
   PubMed Web of Science ®Google Scholar
• Voena C, Chiarle R. The battle against ALK resistance: successes and setbacks. Expert Opin Investig Drugs 2012;21:1751-4
   PubMed Web of Science ®Google Scholar
• Pfizer, Inc. Preparation of heterocyclic derivatives such as 2-aminopyridine and 3-aminopyridazine derivatives as anaplastic lymphoma kinase (ALK) inhibitors for the treatment of diseases. WO2011138751; 2011
   Google Scholar
• Xcovery, Inc. Substituted pyridazine carboxamide compounds as kinase inhibitor compounds. WO2099154769; 2009
   Google Scholar
• Xcovery Holding Co., LLC. Preparation of pyridazinecarboxamide derivatives for use as anaplastic lymphoma kinase inhibitors. WO2012048259; 2012
   Google Scholar
• Lovly CM, Heuckmann JM, De Stanchina E, et al. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors. Cancer Res 2011;71:4920-31
   PubMed Web of Science ®Google Scholar
• NCT01625234. Phase 1, first-in-human, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of X-396 in patients with advanced solid tumors. Available from: www.clinicaltrials.gov
   Google Scholar
• Xcovery Holding Co., LLC. Preparation of pyridazinecarboxamide derivatives for use as anaplastic lymphoma kinase inhibitors. WO2012048258; 2012
   Google Scholar
• Eternity Bioscience, Inc. Phosphorus containing compounds as protein kinase inhibitors. WO2012116050; 2012
   Google Scholar
• Ariad. Preparation of phosphorus derivatives as kinase inhibitors. WO2009143389; 2009
   Google Scholar
• Liming S, Hewitt MC. The kinetic isotope effect in the search for deuterated drugs. Drug News Perspect 2010;23:398-04
   Google Scholar
• Manley PW, Blasco F, Mestan J, Aichholz R. The kinetic deuterium isotope effect as applied to metabolic deactivation of imatinib to the des-methyl metabolite, CGP74588. Bioorg Med Chem 2013;21:3231-9
   PubMed Web of Science ®Google Scholar
• Teligene Ltd. Preparation of 3-[1-(dichlorofluorophenyl)ethoxy]-5-[l-(piperidin-4-yl)-lH-pyrazol-4-yl]pyridin-2-amine derivatives as kinase inhibitors. WO2013041038; 2013
   Google Scholar
• Concert Pharmaceuticals, Inc. Derivatives of pyrazole-substituted amino-heteroaryl compounds for treatment of cancer and proliferative diseases. WO2012119006; 2012
   Google Scholar
• Pfizer, Inc. Macrocyclic derivatives for the treatment of proliferative diseases. WO2013132376; 2013
   Google Scholar
• OSI Pharmaceuticals, LLC. Preparation of fused bicyclic heterocycles as kinase inhibitors. WO2012158658; 2012
   Google Scholar
• OSI Pharmaceuticals, Inc. Substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrazines as inhibitors of c-Met and RON tyrosine kinase receptor and their preparation, pharmaceutical compositions and use in the treatment of cancer. WO2010059771; 2010. US20110224191; 2011
   Google Scholar
• KBP Biomedical Co, Ltd. Preparation of heterocycles as anaplastic lymphoma kinase (ALK) inhibitors. CN102443009; 2012
   Google Scholar
• Ghose AK, Herbertz T, Pippin DA, et al. Knowledge based prediction of ligand binding modes and rational inhibitor design for kinase drug discovery. J Med Chem 2008;51:5149-71
   PubMed Web of Science ®Google Scholar
• van Linden OPJ, Kooistra AJ, Leurs R, et al. KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space. J Med Chem 2013; asap article; dx; doi.org/10.1021/jm400378w
   Google Scholar
• Shaw AT, Camidge DR, Felip E, et al. Results of a first-in human phase I study of the ALK inhibitor LDK378 in advanced solid tumors [abstract 4400]. Ann Oncol 2012;23(Suppl 9):ix153
   Google Scholar
• NCT01947608. Expanded treatment protocol with LDK378 in ALK(+) NSCLC. Available from: www.clinicaltrials.gov
   Google Scholar
• Marsilje TH, Pei W, Chen B, et al. Synthesis, structure−activity relationships, and in vivo efficacy of the novel potent and selective Anaplastic Lymphoma Kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isoprop ylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem 2013;56:5675-90
   PubMed Web of Science ®Google Scholar
• Novartis. Preparation of N,N'-diarylpyrimidinediamine for use as protein kinase inhibitors. WO2008073687; 2008
   Google Scholar
• Park BK, Boobis A, Clarke S, et al. Managing the challenge of chemically reactive metabolites in drug development. Nat Rev Drug Discov 2011;10:292-06
   PubMed Web of Science ®Google Scholar
• Wells-Knecht KJ, Ott GR, Cheng M, et al. 2,7-Disubstituted-pyrrolotriazine kinase inhibitors with an unusually high degree of reactive metabolite formation. Chem Res Toxicol 2011;24:1994-2003
   Google Scholar
• IRM LLC. Methods of using EML4-ALK+ fusion protein inhibitors for treatment of cancer. WO2012106540; 2012
   Google Scholar
• Novartis AG. Preparation of crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine for treatment of disorders and cancers. WO2012082972; 2012
   Google Scholar
• Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors. US20128148391; 2012
   Google Scholar
• Ott GR, Tripathy R, Cheng M, et al. Discovery of a potent inhibitor of anaplastic lymophoma kinase with in vivo antitumor activity. ACS Med Chem Lett 2010;1:493-8
   Google Scholar
• Mesaros EF, Burke JP, Parrish JD, et al. Novel 2,3,4,5-tetrahydrobenzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with Antitumor efficacy in ALCL mouse models. Bioorg Med Chem Lett 2011;21:463-6
   PubMed Web of Science ®Google Scholar
• Zificsak CA, Theroff JP, Aimone LD, et al. Methanesulfonamido-cyclohexylamine derivatives of 2,4-diaminopyrimidine as potent ALK inhibitors. Bioorg Med Chem Lett 2011;21:3877-80
   PubMed Web of Science ®Google Scholar
• Gingrich DE, Lisko JG, Curry MA, et al. Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase. J Med Chem 2012;55:4580-93
   PubMed Web of Science ®Google Scholar
• Allwein SP, Roemmele RC, Haley JJ Jr, et al. Development and scale-up of an optimized route to the ALK inhibitor CEP-28122. Org Process Res Dev 2012;16:148-55
   Google Scholar
• Cheng M, Quail MR, Gingrich DE, et al. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers. Mol Cancer Ther 2012;11:670-9
   PubMed Web of Science ®Google Scholar
• NCT01922752. To determine the maximum tolerated dose of oral CEP-37440 in patients with advanced or metastatic solid tumors. Available from: www.clinicaltrials.gov
   Google Scholar
• Astellas Pharma, Inc. Method for producing di(arylamino)aryl compound, and synthetic intermediate therefor. WO2012102393; 2012
   Google Scholar
• NCT01284192. Study of an investigational drug, asp3026, in patients with advanced malignancies (solid tumors and B-cell lymphoma). Available from: www.clinicaltrials.gov [Accessed on 2013]
   Google Scholar
• Katayama R, Khan TM, Benes C, et al. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci USA 2011;108:7535-40
   PubMed Web of Science ®Google Scholar
• Gettinger S, Weiss GJ, Salgia R, et al. A first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies [abstract 4390]. Ann Oncol 2012;23(Suppl 9):ix152
   Google Scholar
• Bossi RT, Saccardo MB, Ardini E, et al. Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors. Biochemistry 2010;49:6813-25
   PubMed Web of Science ®Google Scholar
• Bryan MC, Whittington DA, Doherty EM, et al. Rapid development of piperidine carboxamides as potent and selective anaplastic lymphoma kinase inhibitors. J Med Chem 2012;55:1698-05
   Google Scholar
• Amgen, Inc. Preparation of pyrimidine compounds that inhibit anaplastic lymphoma kinase and are useful in the treatment of cancers. WO2011143033; 2011
   Google Scholar
• Incyte. Macrocyclic compounds as kinase inhibitors and their preparation, pharmaceutical compositions and their use in the treatment of JAK/ALK-associated diseases. WO2009132202; 2009
   Google Scholar
• Incyte Corp. Preparation of oxatetraazatetracyclotricosanonaene derivatives and analogs for use as JAK and ALK inhibitors. WO2010085597; 2010
   Google Scholar
• Cephalon, Inc. Macrocyclic compounds as ALK, FAK and JAK2 inhibitors and their preparation and use for the treatment of ALK-, FAK- and JAK2-mediated diseases. WO2012125603; 2012
   Google Scholar
• Breslin HJ, Lane BM, Ott GR, et al. Design, synthesis, and Anaplastic Lymphoma Kinase (ALK) inhibitory activity for a novel series of 2,4,8,22-tetraazatetracyclo[14.3.1.13,7.19,13]-docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaene macrocycles. J Med Chem 2012;55:449-64
   PubMed Web of Science ®Google Scholar
• Abbott Laboratories. Preparation of pyrrolopyrimidines as inhibitors of FAK and ALK kinases for treatment of cancers and other diseases. WO2012045195; 2012
   Google Scholar
• Cephalon, Inc. Preparation of pyrrolotriazines as inhibitors of ALK and JAK2 kinases for treating proliferative diseases. US20128471005; 2012
   Google Scholar
• Ott GR, Wells GJ, Thieu TV, et al. 2,7-Disubstituted-pyrrolo[2,1-f][1,2,4]triazines: new variant of an old template and application to the discovery of anaplastic lymphoma kinase (ALK) inhibitors with in vivo antitumor activity. J Med Chem 2011;54:6328-41
   PubMed Web of Science ®Google Scholar
• Zificsak CA, Gingrich DE, Breslin HJ, et al. Optimization of a novel kinase inhibitor scaffold for the dual inhibition of JAK2 and FAK kinases. Bioorg Med Chem Lett 2011;22:133-7
   Google Scholar
• Weinberg LR, Albom MS, Angeles TS, et al. 2,7-Pyrrolo[2,1-f][1,2,4]triazines as JAK2 inhibitors: modification of target structure to minimize reactive metabolite formation. Bioorg Med Chem Lett 2011;21:7325-30
   Google Scholar
• Mesaros EF, Thieu TV, Wells GJ, et al. Strategies to mitigate the bioactivation of 2-anilino-7-aryl-pyrrolo[2,1-f][1,2,4]triazines: identification of orally bioavailable, efficacious ALK inhibitors. J Med Chem 2012;55:115-25
   Google Scholar
• Thieu T, Sclafani JA, Levy DV, et al. Discovery and process synthesis of novel 2,7-pyrrolo[2,1-f][1,2,4]triazines. Org Lett 2011;13:4204-7
   Google Scholar
• Cephalon, Inc. Preparation of imidazo[4,5-b]pyridine derivatives as ALK and JAK modulators for the treatment of proliferative disorders. WO2013116291; 2013
   Google Scholar
• Learn KS, Wagner JC, Albom MS, et al. Design of 7-amino-6-chloro-3H-imidazo[4,5-b]pyridine scaffold from 5-chloro-2,4-diaminopyrimidine pharmacophore: identification of potent inhibitors of anaplastic lymphoma kinase. Med Chem Commun 2012;3:1138-42
   Google Scholar
• AstraZeneca AB. Preparation of substituted pyrimidinamines as ALK kinase inhibitors. US20120028924; 2012.WO2012017239; 2012
   Google Scholar
• Burns CJ, Bourke DG, Andrau L, et al. Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs). Bioorg Med Chem Lett 2009;19:5887-92
   PubMed Web of Science ®Google Scholar
• Chugai Pharmaceutical Co. Preparation of tetracyclic compounds such as 11-oxo-5,6-dihydrobenzo[b]carbazole-3-carbonitrile derivatives as anaplastic lymphoma kinase (ALK) inhibitors. WO2010143664; 2010. US20120083488; 2012
   Google Scholar
• Kinoshita K, Ono Y, Emura T, et al. Discovery of novel tetracyclic compounds as anaplastic lymphoma kinase inhibitors. Bioorg Med Chem Lett 2011;21:3788-93
   PubMed Web of Science ®Google Scholar
• Kinoshita K, Kobayashi T, Asoh K, et al. 9-Substituted 6,6-dimethyl-11-oxo-6,11-dihydro-5Hbenzo[b]carbazoles as highly selective and potent anaplastic lymphoma kinase inhibitors. J Med Chem 2011;54:6286-94
   PubMed Web of Science ®Google Scholar
• Kinoshita K, Asoh K, Furuichi N, et al. Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802). Bioorg Med Chem 2012;20:1271-80
   PubMed Web of Science ®Google Scholar
• Sakamoto H, Tsukaguchi T, Hiroshima S, et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011;19:679-90
   PubMed Web of Science ®Google Scholar
• NCT01588028. A clinical study testing the safety and efficacy of CH5424802/RO5424802 in patients with alk positive non-small cell lung cancer. Available from: www.clinicaltrials.gov
   Google Scholar
• NCT01871805. A study of CH5424802/RO5424802 in patients with ALK-rearranged non-small cell lung cancer. Available from: www.clinicaltrials.gov
   Google Scholar
• Seto T, Kiura K, Nishio M, et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study. Lancet Oncol 2013;14:590-8
   PubMed Web of Science ®Google Scholar
• Abbott Laboratories. Preparation of piperazinylphenylaminopicolinamides as ALK inhibitors. WO2012100135; 2012
   Google Scholar
• Abbott Laboratories. Preparation of bicyclic carboxamide inhibitors of kinases for cancer treatment. WO2012097478; 2012
   Google Scholar
• Abbott Laboratories. Preparation of bicyclic carboxamide inhibitors of kinases for treating cancer. WO2012097684; 2012
   Google Scholar
• Abbott Laboratories. Bicyclic heterocycles as anaphastic lymphoma kinase (ALK) inhibitors and their preparation and use for the treatment of cancer. WO2012097479; 2012
   Google Scholar
• Abbott Laboratories. Bicyclic heterocycles as ALK inhibitors and their preparation and use for the treatment of cancer. WO2012097683; 2012
   Google Scholar
• Abbott Laboratories. Bicyclic heterocycles as ALK inhibitors and their preparation and use for the treatment of cancer. WO2012097682; 2012
   Google Scholar
• Amgen, Inc. Preparation of azabenzimidazole derivatives and analogs for use as anaplastic lymphoma kinase inhibitors. WO2012018668; 2012
   Google Scholar
• Lewis RT, Bode CM, Choquette DM, et al. The discovery and optimization of a novel class of potent, selective, and orally bioavailable Anaplastic Lymphoma Kinase (ALK) inhibitors with potential utility for the treatment of cancer. J Med Chem 2012;55:6523-40
   PubMed Web of Science ®Google Scholar
• Gregor. Preparation of imidazo[4,5-f]isoindole derivatives as tyrosine kinase inhibitors for treating cancer. US20120065233; 2012
   Google Scholar
• GTX, Inc. Tyrosine kinase inhibitors. WO2012037155; 2012
   Google Scholar
• ChemBridge Corp. Preparation of imidazo[4,5-f]isoindole derivatives as tyrosine kinase inhibitors. WO2009117097; 2009
   Google Scholar
• Dana-Farber Cancer Institute, Inc. Preparation of indazole derivatives for use in treatment and prevention of kinase-mediated diseases. WO2011115725; 2011
   Google Scholar
• Nerviano Medical Sciences. Indazole derivatives as kinase inhibitors for the treatment of cancer and their preparation. WO2008074749; 2008
   Google Scholar
• Nerviano Medical Sciences. Preparation of substituted indazole derivatives for use as kinase inhibitors. WO2009013126; 2009
   Google Scholar
• Deng X, Zhou W, Weisberg E, et al. An amino-indazole scaffold with spectrum selective kinase inhibition of FLT3, PDGFRalpha and kit. Bioorg Med Chem Lett 2012;22:4579-84
   Google Scholar
• Pierre Fabre Medicament. Preparation of azaindazole or diazaindazole derivatives as ALK, Abl and/or c-Sr kinase inhibitors for treating cancer, inflammation and neurodegenerative diseases. WO2012101239; 2012
   Google Scholar
• Pierre Fabre Medicament. Preparation of pyrazolopyridine derivatives as ALK kinase inhibitors for treating cancer. WO2011045344; 2011
   Google Scholar
• Pierre Fabre Medicament. Preparation of tri- and tetracyclic pyrazolo[3,4-b]pyridine compounds as antineoplastic agent. WO2012139134; 2012
   Google Scholar
• Exelixis, Inc. Preparation of pyrazolo[3,4-c]isoquinoline derivatives as anaplastic lymphoma kinase modulators. US20070032515; 2007
   Google Scholar
• University of Utah Research Foundation. Substituted N-phenylpyrimidin-2-amine analogs as inhibitors of the Axl kinase. WO2012135800; 2012
   Google Scholar
• Korea Institute of Science and Technology. Preparation of 2,7-substituted thieno[3,2-d]pyrimidine compounds as protein kinase inhibitors. WO2011049332; 2011
   Google Scholar
• Korea Institute of Science and Technology. Preparation of 2,4,7-substituted thieno[3,2-d]pyrimidine compounds as protein kinase inhibitors. WO2011062372; 2011
   Google Scholar
• University Health Network. Preparation of spiro cyclopropylindolinone compounds as Kinase inhibitors for treating cancer. WO2010115279; 2010
   Google Scholar
• Genosco and Oscotec, Inc. Protein Kinase inhibitors. WO2011053861; 2011
   Google Scholar
• Korea Institute of Science and Technology. Preparation of novel 1,6-disubstituted indole compounds as protein kinase inhibitors. WO2011052923; 2011
   Google Scholar
• Hanmi Pharm Co. Preparation of thieno[3,2-d]pyrimidine derivatives having inhibitory activity for protein kinases. WO2013100632; 2013
   Google Scholar
• Hanmi Pharmaceutical Co, Ltd. Preparation of bicyclicheteroaryl derivatives for use as protein kinase inhibitors. WO2011093672; 2011
   Google Scholar
• Hallberg B, Palmer RH. Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Can 2013;13:685-700
   PubMed Web of Science ®Google Scholar
• Available from: www.clinicaltrials.gov
   Google Scholar
• af Gennäs GB, Mologni L, Ahmed S, et al. Design, synthesis, and biological activity of urea derivatives as anaplastic lymphoma kinase inhibitors. ChemMedChem 2011;6:1680-92
   Google Scholar
• NCT01449461. A Phase I/II study of the oral ALK/EGFR inhibitor AP26113. Available from: www.clinicaltrials.gov [Accessed on 2013]
   Google Scholar
• NCT01801111. A study of RO5424802 in patients with non-small cell lung cancer who have ALK mutation and failed crizotinib treatment. Available from: www.clinicaltrials.gov [Accessed on 2013]
   Google Scholar
• NCT01441128. Phase I PF-02341066 and PF-00299804 for advanced non-small cell lung cancer. Available from: www.clinicaltrials.gov [Accessed on 2013]
   Google Scholar
• NCT01772797. Phase Ib study of LDK378 and AUY922 in ALK-rearranged non-small cell lung cancer. Available from: www.clinicaltrials.gov [Accessed on 2013]
   Google Scholar
• Sang J, Acquaviva J, Friedland JC, et al. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non -small cell lung cancer. Can Discov 2013;3:430-43
   PubMed Web of Science ®Google Scholar
• Dymock BW, See CS. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 – 2012. Expert Opin Ther Patents 2013;23:449-501
   PubMed Web of Science ®Google Scholar
• Mologni L. Inhibitors of the anaplastic lymphoma kinase. Expert Opin Investig Drugs 2012;21:985-94
   PubMed Web of Science ®Google Scholar